Product
PIP/TAZ FDC
1 clinical trial
2 indications
Indication
Hospital-Acquired Bacterial PneumoniaClinical trial
A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaStatus: Completed, Estimated PCD: 2022-07-12